Citing Lack of Benefit, NIH Halts Trial of Hydroxychloroquine for COVID-19

Clara T. Fryman

News Picture: Citing Lack of Benefit, NIH Halts Trial of Hydroxychloroquine for COVID-19By E.J. Mundell
HealthDay Reporter

MONDAY, June 22, 2020 (HealthDay News) — The U.S. Countrywide Institutes of Heath declared Saturday that it was stopping a scientific demo of hydroxychloroquine, a drug lengthy supported by President Donald Trump as a probable panacea for COVID-19.

“A knowledge and protection monitoring board satisfied late Friday and established that while there was no hurt, the review drug was incredibly unlikely to be useful to hospitalized clients with COVID-19,” the NIH said in a information release.

As the company mentioned, hydroxychloroquine is a malaria drug that does have antiviral activity. Early in the novel coronavirus

Read More

Subscribe US Now